Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT1 | Q99873 | 2/20 | 0.42 |
| ▸ | LRRK2 | Q5S007 | 15/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | NSD2 | O96028 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | PRMT6 | Q96LA8 | 2/20 | 0.35 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17469503 | 0.93 | PRMT1 (0.46) | PRMT1LRRK2PRMT6PRMT8 | |
| SCHEMBL17469452 | 0.93 | PRMT1 (0.47) | PRMT1LRRK2PRMT6PRMT8 | |
| SCHEMBL17469445 | 0.89 | FADS1 (0.40) | PRMT1SMN1; SMN2GSK3B | |
| SCHEMBL16120045 | 0.88 | TTK (0.39) | PRMT1KDM4E | |
| SCHEMBL17469496 | 0.87 | PRMT1 (0.39) | PRMT1LRRK2KDM4EPRMT6PRMT8 | |
| SCHEMBL17469470 | 0.87 | HSP90AA1 (0.37) | PRMT1ALDH1A1 | |
| SCHEMBL16119992 | 0.86 | FADS1 (0.41) | PRMT1 | |
| SCHEMBL16129385 | 0.85 | PRMT1 (0.39) | PRMT1LRRK2PRMT6PRMT8 | |
| SCHEMBL20066384 | 0.83 | PRMT1 (0.43) | PRMT1LRRK2 | |
| SCHEMBL17469513 | 0.83 | PRMT5 (0.40) | PRMT1LRRK2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180105497-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2018-04-19 | — | — | US | disclosed |
| US-9765035-B2 | Arginine methyltransferase inhibitors and uses thereof | Epizyme, Inc. (US) | 2017-09-19 | — | — | US | disclosed |
| US-20160024017-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2016-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024017-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | PRMT1, PRMT3, PRMT5 | PRMT1 1/4885LRRK2 972/4885KDM4E 175/4885 |
| US-20180105497-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | PRMT1, PRMT3, PRMT5 | PRMT1 1/4885LRRK2 972/4885KDM4E 175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.